A novel study design for antibiotic trials in acute exacerbations of copd

Maestral methodology

Robert Wilson, Antonio R Anzueto, Marc Miravitlles, Pierre Arvis, Geneviève Faragó, Daniel Haverstock, Mila Trajanovic, Sanjay Sethi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Antibiotics, along with oral corticosteroids, are standard treatments for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The ultimate aims of treatment are to minimize the impact of the current exacerbation, and by ensuring complete resolution, reduce the risk of relapse. In the absence of superiority studies of antibiotics in AECOPD, evidence of the relative efficacy of different drugs is lacking, and so it is difficult for physicians to select the most effective antibiotic. This paper describes the protocol and rationale for MAESTRAL (moxifoxacin in AECBs [acute exacerbation of chronic bronchitis] trial; www.clinicaltrials.gov: NCT00656747), one of the frst antibiotic comparator trials designed to show superiority of one antibiotic over another in AECOPD. It is a prospective, multinational, multicenter, randomized, double-blind controlled study of moxifloxacin (400 mg PO [per os] once daily for 5 days) vs amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days) in outpatients with COPD and chronic bronchitis suffering from an exacerbation. MAESTRAL uses an innovative primary endpoint of clinical failure: the requirement for additional or alternate treatment for the exacerbation at 8 weeks after the end of antibiotic therapy, powered for superiority. Patients enrolled are those at high-risk of treatment failure, and all are experiencing an Anthonisen type I exacerbation. Patients are stratified according to oral corticosteroid use to control their effect across antibiotic treatment arms. Secondary endpoints include quality of life, symptom assessments and health care resource use. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

Original languageEnglish (US)
Pages (from-to)373-383
Number of pages11
JournalInternational Journal of COPD
Volume6
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Anti-Bacterial Agents
Chronic Obstructive Pulmonary Disease
Chronic Bronchitis
Adrenal Cortex Hormones
Therapeutics
Amoxicillin-Potassium Clavulanate Combination
Symptom Assessment
Health Resources
Treatment Failure
Double-Blind Method
Outpatients
Quality of Life
Delivery of Health Care
Physicians
Recurrence
Pharmaceutical Preparations

Keywords

  • AECOPD
  • Amoxicillin/clavulanic acid
  • Antibiotic
  • Clinical trial design
  • Exacerbation
  • Moxifloxacin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health
  • Health Policy
  • Medicine(all)

Cite this

A novel study design for antibiotic trials in acute exacerbations of copd : Maestral methodology. / Wilson, Robert; Anzueto, Antonio R; Miravitlles, Marc; Arvis, Pierre; Faragó, Geneviève; Haverstock, Daniel; Trajanovic, Mila; Sethi, Sanjay.

In: International Journal of COPD, Vol. 6, No. 1, 2011, p. 373-383.

Research output: Contribution to journalArticle

Wilson, R, Anzueto, AR, Miravitlles, M, Arvis, P, Faragó, G, Haverstock, D, Trajanovic, M & Sethi, S 2011, 'A novel study design for antibiotic trials in acute exacerbations of copd: Maestral methodology', International Journal of COPD, vol. 6, no. 1, pp. 373-383. https://doi.org/10.2147/COPD.S21071
Wilson, Robert ; Anzueto, Antonio R ; Miravitlles, Marc ; Arvis, Pierre ; Faragó, Geneviève ; Haverstock, Daniel ; Trajanovic, Mila ; Sethi, Sanjay. / A novel study design for antibiotic trials in acute exacerbations of copd : Maestral methodology. In: International Journal of COPD. 2011 ; Vol. 6, No. 1. pp. 373-383.
@article{4d14554bcc1342a5bbd69b3744258e5f,
title = "A novel study design for antibiotic trials in acute exacerbations of copd: Maestral methodology",
abstract = "Antibiotics, along with oral corticosteroids, are standard treatments for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The ultimate aims of treatment are to minimize the impact of the current exacerbation, and by ensuring complete resolution, reduce the risk of relapse. In the absence of superiority studies of antibiotics in AECOPD, evidence of the relative efficacy of different drugs is lacking, and so it is difficult for physicians to select the most effective antibiotic. This paper describes the protocol and rationale for MAESTRAL (moxifoxacin in AECBs [acute exacerbation of chronic bronchitis] trial; www.clinicaltrials.gov: NCT00656747), one of the frst antibiotic comparator trials designed to show superiority of one antibiotic over another in AECOPD. It is a prospective, multinational, multicenter, randomized, double-blind controlled study of moxifloxacin (400 mg PO [per os] once daily for 5 days) vs amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days) in outpatients with COPD and chronic bronchitis suffering from an exacerbation. MAESTRAL uses an innovative primary endpoint of clinical failure: the requirement for additional or alternate treatment for the exacerbation at 8 weeks after the end of antibiotic therapy, powered for superiority. Patients enrolled are those at high-risk of treatment failure, and all are experiencing an Anthonisen type I exacerbation. Patients are stratified according to oral corticosteroid use to control their effect across antibiotic treatment arms. Secondary endpoints include quality of life, symptom assessments and health care resource use. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.",
keywords = "AECOPD, Amoxicillin/clavulanic acid, Antibiotic, Clinical trial design, Exacerbation, Moxifloxacin",
author = "Robert Wilson and Anzueto, {Antonio R} and Marc Miravitlles and Pierre Arvis and Genevi{\`e}ve Farag{\'o} and Daniel Haverstock and Mila Trajanovic and Sanjay Sethi",
year = "2011",
doi = "10.2147/COPD.S21071",
language = "English (US)",
volume = "6",
pages = "373--383",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - A novel study design for antibiotic trials in acute exacerbations of copd

T2 - Maestral methodology

AU - Wilson, Robert

AU - Anzueto, Antonio R

AU - Miravitlles, Marc

AU - Arvis, Pierre

AU - Faragó, Geneviève

AU - Haverstock, Daniel

AU - Trajanovic, Mila

AU - Sethi, Sanjay

PY - 2011

Y1 - 2011

N2 - Antibiotics, along with oral corticosteroids, are standard treatments for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The ultimate aims of treatment are to minimize the impact of the current exacerbation, and by ensuring complete resolution, reduce the risk of relapse. In the absence of superiority studies of antibiotics in AECOPD, evidence of the relative efficacy of different drugs is lacking, and so it is difficult for physicians to select the most effective antibiotic. This paper describes the protocol and rationale for MAESTRAL (moxifoxacin in AECBs [acute exacerbation of chronic bronchitis] trial; www.clinicaltrials.gov: NCT00656747), one of the frst antibiotic comparator trials designed to show superiority of one antibiotic over another in AECOPD. It is a prospective, multinational, multicenter, randomized, double-blind controlled study of moxifloxacin (400 mg PO [per os] once daily for 5 days) vs amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days) in outpatients with COPD and chronic bronchitis suffering from an exacerbation. MAESTRAL uses an innovative primary endpoint of clinical failure: the requirement for additional or alternate treatment for the exacerbation at 8 weeks after the end of antibiotic therapy, powered for superiority. Patients enrolled are those at high-risk of treatment failure, and all are experiencing an Anthonisen type I exacerbation. Patients are stratified according to oral corticosteroid use to control their effect across antibiotic treatment arms. Secondary endpoints include quality of life, symptom assessments and health care resource use. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

AB - Antibiotics, along with oral corticosteroids, are standard treatments for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The ultimate aims of treatment are to minimize the impact of the current exacerbation, and by ensuring complete resolution, reduce the risk of relapse. In the absence of superiority studies of antibiotics in AECOPD, evidence of the relative efficacy of different drugs is lacking, and so it is difficult for physicians to select the most effective antibiotic. This paper describes the protocol and rationale for MAESTRAL (moxifoxacin in AECBs [acute exacerbation of chronic bronchitis] trial; www.clinicaltrials.gov: NCT00656747), one of the frst antibiotic comparator trials designed to show superiority of one antibiotic over another in AECOPD. It is a prospective, multinational, multicenter, randomized, double-blind controlled study of moxifloxacin (400 mg PO [per os] once daily for 5 days) vs amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days) in outpatients with COPD and chronic bronchitis suffering from an exacerbation. MAESTRAL uses an innovative primary endpoint of clinical failure: the requirement for additional or alternate treatment for the exacerbation at 8 weeks after the end of antibiotic therapy, powered for superiority. Patients enrolled are those at high-risk of treatment failure, and all are experiencing an Anthonisen type I exacerbation. Patients are stratified according to oral corticosteroid use to control their effect across antibiotic treatment arms. Secondary endpoints include quality of life, symptom assessments and health care resource use. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

KW - AECOPD

KW - Amoxicillin/clavulanic acid

KW - Antibiotic

KW - Clinical trial design

KW - Exacerbation

KW - Moxifloxacin

UR - http://www.scopus.com/inward/record.url?scp=81055123895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81055123895&partnerID=8YFLogxK

U2 - 10.2147/COPD.S21071

DO - 10.2147/COPD.S21071

M3 - Article

VL - 6

SP - 373

EP - 383

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

IS - 1

ER -